A process for producing new anticancer drugs such that the drugs can be administered in a nontoxic, proto-drug form and, subsequent to a time delay which allows for differential concentration in the targer cancer or invasive tissues or cells, the non-toxic drug is then modified by an activation drug to selectively provide toxic levels of a pharmacologically active agent to the target issue.
一种生产新型抗癌药物的方法,使药物可以以无毒的原型药物形式给予,并在延迟一段时间后,允许在目标癌细胞或侵入性组织或细胞中出现差异浓度,然后通过激活药物修改无毒药物,以选择性地向目标组织提供药理活性成分的毒性
水平。